Donald Trump & Bristol Myers Squibb

Donald Trump: Donald Trump announced new tariffs on various imported goods, aiming to boost domestic manufacturing and reduce the budget deficit, despite warnings of increased inflation and harm to consumers.

Bristol Myers Squibb: Bristol Myers Squibb, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.

Donald Trump: Donald Trump's administration has prioritized domestic investment, and AstraZeneca has already committed $50 billion to US manufacturing. The merger would likely need approval from his antitrust authorities.

Bristol Myers Squibb: Bristol Myers Squibb is the target of the potential merger, which would provide it with a significant premium and access to AstraZeneca's pipeline. Its shares have risen 43% in the past year, and the deal could further boost its valuation.

Donald Trump: Held off on strikes against Iran, easing oil prices. Pushed for lower rates.

Bristol Myers Squibb: Reportedly in merger talks with AstraZeneca, which could create a $400 billion drugmaker.

Bristol Myers Squibb: Bristol Myers Squibb is one of the major drugmakers that has reached pricing agreements with the Donald Trump administration to avoid the new tariffs.